Business
Faron files patent application for Traumakine
Faron files patent application for Traumakine.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 5448Q Faron Pharmaceuticals Oy 01 March 2016 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \n \nFaron files patent application to further strengthen protection for its novel Traumakine®\n(FP-1201-lyo) formulation\n \nTURKU - FINLAND, 1 March 2016 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the drug discovery and development company is pleased to announce that it has filed a national application for a new formulation patent in Finland with filings to be expanded over the next two years to almost all countries worldwide under the Patent Co-operation Treaty (PCT). The patent further protects Faron's final FP-1201-lyo (lyophilised interferon-beta or Traumakine®) formulation for the intravenous treatment of acute respiratory distress syndrome (\"ARDS\") and other vascular diseases.\nInterferon-beta, especially if freeze-dried, is known to form aggregates or stick to container surfaces, requiring careful control of dosing and in-use stability during administration. Faron has developed a proprietary new product formulation for which tests have shown almost 100 per cent recovery of solubilised interferon-beta for intravenous use. With this patent formulation filing, Faron is seeking to protect this discovery for the next 20 years. Based on patent database searches, no similar formulation has been reported previously.\nDr Markku Jalkanen, CEO of Faron, said: \"As of today, our Traumakine treatment is the only known intravenously administered human interferon-beta preparation and it is important that dosing is optimal for patients lacking peripheral circulation, as is the case with ARDS patients. We have carefully tested various ingredients to optimise interferon-beta use in these patients and have now completed all necessary tests for patent purposes. If our claims are approved, we could have a proprietary product for the next two decades, further increasing Traumakine's significant, commercial potential. We already have new use patents for interferon-beta in ischaemic conditions and multi organ failure, and this new formulation patent will reinforce our global patent protection strategy\".\nThe new formulation, which has not previously been made public, is already in use in Faron's pivotal, pan-European INTEREST trial, the recruitment of which the Company expects to be co...